Twist Bioscience TWST Stock Jumps On Lilly AI Deal
Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.
How this was made
The 30-second read
Why it matters
The Lilly agreement provides a tangible catalyst that validates Twist's platform and may accelerate revenue growth, reinforcing the recent price surge.
Market read
A fresh, material partnership drives a double‑digit intraday rally, offering traders a timely entry point.
What to watch
Potential dilution from future financing rounds and reliance on a single large‑pharma partner could increase risk.
Background
Twist Bioscience reported Q3 FY26 revenue of $118.4M (+23% YoY) and raised full‑year guidance, while reaffirming a path to EBITDA breakeven in Q4 FY26.
Ticker impact
Twist Bioscience shares jumped 11.4% after announcing a new agreement with Eli Lilly to provide antibody data for Lilly's AI/ML TuneLab platform.
Potential continuation of intraday rally; watch for breakout above $165 if volume sustains.
Large‑cap pharma partner, double‑digit price move, and fresh guidance create a strong near‑term bias.
Market effects
Highlights growing demand for synthetic biology tools in AI‑driven drug discovery, benefitting the broader biotech tools sector.
U.S. biotech and pharma stocks may see modest lift as the partnership underscores AI integration trends.
Signals a shift toward AI‑enabled R&D globally, potentially influencing biotech investment sentiment worldwide.
Counterpoint
The deal may be limited in scope and revenue, and Twist's ongoing losses could cap upside if execution falters.
Key entities
- companyTwist Bioscience Corporation
Synthetic DNA and NGS tools provider (NASDAQ: TWST).
- companyEli Lilly and Co.
Pharmaceutical giant partnering with Twist for AI‑driven antibody design.
